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Imaging for Improving Therapy
A Stop on the Way to Improve Outcomes?*
Y. Chandrashekhar, MD
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CKnowledge and timber shouldn’t be much used
till they are seasoned
—Oliver Wendell Holmes (1)
Despite rapid advances in diagnosis and greater
availability of effective cardiac therapies, utilization
rates for these evidence-based treatments have been
suboptimal in most cardiac conditions. Less than
optimal rates of drug prescription, use, and adher-
ence contribute to this problem. Multiple studies,
including the REACH (Reduction of Athero-
thrombosis for Continued Health) registry involv-
ing 67,888 patients, confirmed a concerning under-
utilization of many drugs shown to favorably alter
See page 574
cardiovascular outcomes (2). Various strategies have
been proposed to improve evidence-based drug
prescription and adherence, but most have had only
modest success. Because a visual picture may be
worth many thousand words of oral or textual
description, 1 strategy that has evoked great interest
is to use cardiac imaging to detect subclinical
disease; moreover, displaying graphic evidence of
coronary artery disease (CAD) that is likely to cause
high-impact events in patients without evidence of
CAD, may impact physician–patient behavior pos-
itively. Imaging not only provides a very refined risk
assessment in CAD, but also offers detailed visual
information of coronary pathology, including
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disclose.hanges in the coronary wall—information not
asily available with other modalities; such com-
ined information might overcome some of the
urrent limitations in medication use and adher-
nce. There is preliminary evidence that visual
mages improve understanding of a threat, increase
elievability of the risk information, and encourage
isk behavior modification (3). Studies with coro-
ary calcium imaging show a benefit in terms of
ncrease in statin use (4,5). Computed tomography
ngiography (CTA) (which presumably would be
sed in a “for-cause testing” population with an
nriched pre-test probability compared with coro-
ary calcium screening studies), with more detailed
nformation, might be similar or better in changing
hysician–patient behavior. A study in this issue of
JACC is one such effort to study the effect of a positive
oronary CTA scan on prescription patterns and change
n cardiovascular risk factors. Cheezum et al. (6) retro-
pectively studied 1,125 patients without known CAD,
ow-risk scores, and mostly atypical chest pain coming for
TA. Pre- and post-CTA prescription patterns for
spirin, statins, and blood pressure medication (1 snap-
hot from databases in the 6 months pre- and post-
TA) and risk factors were evaluated. Similar to prior
tudies in symptomatic (7) as well as asymptomatic
atients coming for screening (8), knowing CTA results
ncreased the frequency of some appropriate prescriptions
nd resulted in improvement of lipid profiles. Not unex-
ectedly, the change was in proportion to the severity of
he imaging abnormality. Similar to all other studies in
his arena, the study was too small to evaluate outcomes.
an Imaging Modify Physician and
atient Behavior?
ardiac imaging in general results in increased
herapy, and the increase is related to the severity of
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583test results. This has been shown in many studies
(4,5,9), many albeit mostly small and limited to
single or few centers using multiple different imaging
modalities and sources of data. Some studies directly
worked on motivating the patient, whereas others had
a more global strategy. Even in the positive studies,
the magnitude of change in medication use still
remains suboptimal, even in those groups with the
highest risk. Nearly one-third of high-risk patients
were not on guideline-recommended medications
post-imaging in the SPARC (Study of Myocardial
Perfusion and Coronary Anatomy Imaging Roles in
Coronary Artery Disease) study (9), and use of
medication diminishes with time following an im-
aging test (8). Data in patients with lower risk are
limited and varied, including in asymptomatic and
symptomatic patients. One recent, well-done study
showed that coronary artery calcium scanning in
2,137 highly motivated, well-educated, middle-
aged asymptomatic volunteers was associated with
better risk factor profiles at a single time point 4
years later. Outcomes, although the study was not
powered for this endpoint, were not different (4).
However, results have not been unanimously
consistent, especially in some of the more robust
studies. A good-sized randomized trial using myo-
cardial perfusion imaging in diabetic patients found
that imaging did not markedly change the use of
appropriate therapy (10). An older randomized
study in active duty military personnel (somewhat
similar risk as in the current paper (6), but younger
age) did not show any benefit, in terms of altering
modifiable risk, by their knowing whether they had
coronary calcium or not. Although intensive case
management helped in lowering modifiable risk,
knowledge of coronary calcium did not add to it
(11). Finally, another well-done randomized study
of carotid plaque imaging failed to change smoking
cessation rates or risk factor profiles even in moti-
vated subjects (12). Notably, the test was positive in
58% of the subjects, thus avoiding the criticism of
other studies that one cannot motivate a change in
behavior if there is no high-risk indictor to start
with. As a comparison, only 15% had a positive
electron beam computed tomography scan in the
O’Malley et al. study (11), and only 9% had 50%
stenosis (and 55% had no CAD at all) in the current
study (6). In a meta-analysis of 7 studies, interven-
tion failed to show that cardiovascular imaging
significantly influenced drug use, smoking cessa-
tion, or diet changes (13) but also demonstrated the
scarcity of high-quality data addressing these issues.
Despite imaging’s attractiveness, its ability to refinecardiovascular risk, and encouraging current data,
many limitations, including the use of highly se-
lected patient populations, low prevalence of abnor-
mal findings, and a lack of outcome data, preclude
the drawing of firm conclusions on its broader
utility for patient motivation or modifying physi-
cian prescription behavior. Some of these studies
did not involve the patient’s physician directly, did
not suggest a pre-defined path for intervening, and
the endpoint depended on recall or a long latency in
follow-up, to a time point 4 years later. Typically,
the effects of short-term counseling do not persist
so long, and factors other than counseling might
have played a role. Not surprisingly, given all these
limitations, some have argued against widespread
adoption of imaging to change behavior (14).
The present study (6), despite being retrospec-
tive, has some novelty even with the prior presence
of at least 3 other studies. The authors used infor-
mation from clinical indication–driven CTA in a
larger group of patients than in many prior studies.
Second, the patient population was unique in that
the subjects were confined to 1 insurance system with
generous benefits, and all their medical data were
largely captive within that health system. Unlike
previous studies, this study did not need to use recall
or similarly less robust strategies to capture data (5).
inally, they were not subject to the confounding
nfluence of variable levels of insurance and drug
vailability.
Does Using Imaging to Modify Physician and
Patient Behavior Change Outcomes?
Even with many studies showing some benefit of
cardiovascular imaging in modifying physician and
patient behavior, one important unanswered ques-
tion is whether CTA information just provokes
more action, or whether the action is associated
with better outcomes. It is worthwhile to remember
that sometimes efforts at more intensive case man-
agement, based on a limited set of indicators, have
resulted in adverse outcomes despite overwhelming
benefit shown in small preliminary studies (15).
Surrogate measures such as increased medication
use or adherence to a prescription strategy may not
reveal what will happen in the long run. Similarly,
studies in other fields have shown that increased
adherence and behavior change with intervention
did not necessarily change outcomes (16). Primary
prevention studies are notoriously affected by low
event rates and need a very large number of patients
to show a benefit—indeed, even the 2,137 patients
in the EISNER (Early Identification of Subclinical
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study were insufficient to show an outcome differ-
ence even with imaging information (4). Although
many guidelines support lipid-lowering therapy for
primary prevention, some have also questioned
whether we may have sufficiently robust data to
subject tens of millions of asymptomatic subjects to
such therapy (17). Future studies will have to show
that acting based on imaging results in unquestion-
able benefits in smaller, better risk-triaged sub-
groups, and randomized outcome studies are
needed before widespread acceptance. The popula-
tion studied in the current study (6) was low risk:
one-half did not have any CAD, and the prescrip-
tion changes in the group with CAD were small;
similar to other previous efforts, the current study
had very few events and thus could not provide
meaningful outcome data. Lipid changes were more
substantial, but the mean changes, especially when
only 37% had both, the pre-CTA and follow-up
lipids, fail to reveal whether the benefit was from a
small group of patients treated aggressively or from
a larger population treated more modestly. Finally,
this snapshot study cannot answer the more impor-
tant question about durability of this effect. Adher-
ence to medication has been notoriously difficult,
adherence diminishes with time (8), and lack of
adherence is a strong factor in suboptimal outcomes
(18). Furthermore, benefits of lipid lowering take a
long time to show up in chronic CAD, and an
increase in 6-month prescription rates might not
hold up long enough for sustained benefit. Thus,
the short-term increase in medication rates in this
study may not be predictive of desirable longer-
term outcomes.
Does Using Imaging to Modify Physician
and Patient Behavior Result in a
More Appropriate Therapeutic Response?
The premise of using imaging for modifying phy-
sician/patient behavior, prescription, and adherence
rests upon appropriate downstream action on the
part of both. Imaging should increase the use of
evidence-based therapies in the high-risk group
while it should also logically avoid unnecessary
therapeutics in the reclassified low-risk group. Al-
though it is logical to think that the current study is
primarily evaluating the effect of CTA, it is more
likely evaluating: 1) a strategy where the “value
proposition” assigned by treating physicians to
CTA results is a major factor; and 2) the physician’s
idea of the “hierarchy of benefit” when treating
various risk factors. Although patient preferencemay also have played a role in this strategy outcome,
this study does not allow one to separate that
contribution from the role of the treating physician.
In the current study, it appears that the cardiologist
performing the CTA did not directly influence the
treating physician or the patient—only their report
conveyed the threat assessment following CTA. It
is not clear whether the recipients were cardiologists
or primary care physicians—their understanding of
what a CTA report means and what “threat value”
it assigns would have been variable. No formal
therapeutic strategy was guiding subsequent treat-
ment; despite being a highly logical option, cur-
rently, there is scant evidence-based data to support
the use of CTA-detected CAD as a pivotal point to
initiate or withhold therapy for risk factors. Thus,
physicians were free to initiate downstream actions
as they chose.
In what the physician believed was the highest-
risk group post-CTA (50% stenosis, 9% of the
population), statin use increased from 69% to 86%
at 6 months post-CTA; about one-half of the
patients had an increase in dose, and one-quarter
had new prescriptions. However, the majority of
patients in this group were hyperlipidemic to start
with before CTA, and many of these patients, who
as a group had the highest Framingham risk score
in this study, may have had an independent reason
to start statins; CTA could just have provided
urgency to the physician to pull the trigger to treat
these patients. Future CTA studies in this arena
will have to show an added value over and above
traditional risk stratification techniques. Interest-
ingly, the odds ratio for statin use, adjusted for
baseline risk factors and medications, was more
pronounced in obstructive versus nonobstructive
CAD. Aspirin use behaved similarly. The treating
physician was probably assigning a different degree
of “threat value” to nonobstructive CAD compared
with obstructive CAD, despite data showing that
the presence of nonobstructive plaque can account
for a significant proportion of events (19). Com-
pared with statins and aspirin, increased utilization
of blood pressure medications was less pronounced.
It is possible that the physician understood CTA
plaque and subsequent events to be primarily de-
pendent upon lipids/platelets that needed intensi-
fied treatment compared with blood pressure, once
again highlighting the role of what the physician
thought was the hierarchy of benefit. In this regard,
the SPARC study also showed a modality-
dependent preference for change in medications—a
positive result on a CTA was more likely to result in
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585a statin prescription compared with a similar result
from perfusion imaging, whereas beta-blocker use
was independent of test modality (9).
The no CAD group (defined as no atherosclero-
sis and no stenosis) also presents very interesting
data. One benefit of imaging should be the reassur-
ance provided by not having CAD or, better yet,
not having any visible plaque. Because not having
CAD portends a very good prognosis, it is logical
that low-risk patients with atypical chest pain and a
negative CTA scan might not need aggressive risk
factor therapy. The no CAD group in this study
was at very low risk for events even before CTA
(Framingham risk score 2.7  3.7, low-density
ipoprotein of 116  31 mg/dl, high-density lipo-
rotein 55  18 mg/dl). Far from any reduction in
tatin or aspirin use with a negative CTA, use of
maging surprisingly resulted in an intensification
f statin therapy in a quarter of patients. This is
ifferent from that seen in other studies where
tatin use decreased following a negative test in
symptomatic patients coming for screening as a
art of a large study (8). It appears that a positive
maging test is interpreted as needing more ag-
ressive therapy, whereas a negative test may be
ccorded less credence for therapeutic decisions.
his is consistent with the highly variable re-
ponse to CTA information among a diverse
roup of physicians. Because these kinds of pa-
ients may form the bulk of patients in the
eneral population, this dichotomy in decision
aking is concerning. Moreover, the risk-to-
enefit ratio of statins might be suboptimal in
his subset of patients in the primary prevention
niverse, and the effect of aspirin may even be
omewhat detrimental. More data evaluating the
afety of downsizing therapy in patients with a
egative imaging test are clearly indicated. CTA
ight not be the best test for this purpose, but
ther imaging, for example, coronary calcium,
ight have an important role in filtering to a
anageable size the millions of patients currently
ecommended for aggressive therapy for primaryInternational prevalence, recognition, J Health Psychol 2Studies evaluating the effect of imaging on down-
stream risk factor levels and outcome are dependent
upon a variety of variables and thus difficult to perform
cleanly in environments like the present study (6) that
are not a part of a randomized trial. A number of steps
need to be reconciled appropriately, including inter-
preting and acting appropriately on the imaging report
(not always done consistently as shown by the
SPARC study), availability of adequate evidence-
based guidelines, instituting changes of adequate mag-
nitude and duration covering multiple nonrelated risk
factors (a problem without a priori treatment algo-
rithms), monitoring for the minimal necessary change
in the target parameters (difficult even in the present
study, where the population was largely captive in
terms of insurance and provider choice—only 37%
had both, pre-CTA and post-CTA lipid levels),
sustaining the improved medication use for the
necessary duration (not available in this study), and
finally, showing changes in outcomes (very few
events were seen, hard events were even fewer, but
the study was not powered to evaluate outcomes).
The population was probably a more disciplined
group with access to high-quality insurance without
significant out-of-pocket expenses and might rep-
resent a better-case scenario. How CTA-based
information would perform in a more real-world
group of patients is debatable. Nevertheless, the
authors are fair in discussing their limitations, and
this study is a useful addition to understanding the
role of CTA in deciding risk-factor control strate-
gies. That said, we now have a sufficient corpus of
uncontrolled studies to move from “imaging for
optimum therapy” to “imaging for optimum out-
comes”—a far more pressing clinical question. All
future investigations in this area will need to address
whether imaging can change outcomes, and ran-
domized trials with outcome endpoints will be very
welcome.
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